INSMED Inc: management transactions · United States · SEC (Form 4)

About INSMED Inc

Insmed Inc. (ticker: INSM) is a U.S.-based biopharmaceutical company listed on the Nasdaq market in the United States (United States). The company is headquartered in Bridgewater, New Jersey, and was founded in 1988. Over time, Insmed has evolved from a specialty biotech into a focused developer of therapies for serious respiratory diseases and underserved rare conditions, with a commercial model centered on specialty medicines and pipeline expansion. The company’s business today is built around a mix of marketed products and clinical-stage programs. Its two key commercial assets are ARIKAYCE (amikacin liposome inhalation suspension), used in the treatment of Mycobacterium avium complex (MAC) lung disease in selected adult patients, and BRINSUPRI (brensocatib), which became the first and only approved treatment for non-cystic fibrosis bronchiectasis (NCFB). The 2025 approval of BRINSUPRI represented a major strategic milestone, materially strengthening Insmed’s growth profile and broadening the company’s long-term commercial opportunity. Insmed’s competitive positioning is that of a specialty respiratory and neutrophil-driven inflammatory disease company. Its scientific strategy relies on differentiated mechanisms, including DPP1 inhibition with brensocatib, and on specialized delivery technology such as the inhaled liposomal formulation used for ARIKAYCE. Beyond its commercial portfolio, the company is advancing TPIP, a late-stage pulmonary hypertension candidate, along with additional exploratory programs in rare respiratory diseases and immunology/inflammation. While the pipeline remains focused, it is aligned with Insmed’s expertise and execution track record. Geographically, Insmed maintains its core operational base in the United States while expanding its international footprint, with offices and activities in Europe as well. This supports a broader commercial strategy, particularly for BRINSUPRI and potential future label expansions. From a competitive standpoint, Insmed is not a broad-based pharmaceutical giant; rather, it competes through specialization, clinical differentiation, and the ability to address markets that have historically lacked effective treatment options. Recent developments highlight improving commercial momentum. In the first quarter of 2026, Insmed reported total revenue of $306.0 million, driven by BRINSUPRI’s launch ramp and continued growth in ARIKAYCE. The company has also communicated that full-year 2026 BRINSUPRI revenue is expected to be at least $1 billion, while ARIKAYCE remains an important revenue base. For French-speaking investors, Insmed therefore stands out as a Nasdaq-listed U.S. biopharma company with a rare-disease focus, multiple clinical catalysts, and an increasingly important commercial platform.